Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 484

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Open access
Provencio, Mariano, Nadal, Ernest, González-Larriba, José L., Martínez-Martí, Alex, Bernabé, Reyes, Bosch-Barrera, Joaquim, Casal-Rubio, Joaquín, Calvo, Virginia, Insa, Amelia, Ponce, Santiago, Reguart, Noemí, de Castro, Javier, Mosquera, Joaquín, Cobo, Manuel, Aguilar, Andrés, López Vivanco, Guillermo, Camps, Carlos, López-Castro, Rafael, Morán, Teresa, Barneto, Isidoro, Rodríguez-Abreu, Delvys, Serna-Blasco, Roberto, Benítez, Raquel, Aguado de la Rosa, Carlos, Palmero, Ramón, Hernando-Trancho, Florentino, Martín-López, Javier, Cruz-Bermúdez, Alberto, Massuti, Bartomeu, Romero, Atocha · 2023 · New England Journal of Medicine

Abstract

BACKGROUND: Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients. METHODS: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety. RESULTS: A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan-Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%). CONCLUSIONS: In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone. (Funded by Bristol Myers Squibb and others; NADIM II ClinicalTrials.gov number, NCT03838159; EudraCT number, 2018-004515-45.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2215530

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 484

Metadata

Authors
Provencio, M., Nadal, E., González-Larriba, J. L., Martínez-Martí, A., Bernabé, R., Bosch-Barrera, J., Casal-Rubio, J., Calvo, V., Insa, A., Ponce, S., Reguart, N., de Castro, J., Mosquera, J., Cobo, M., Aguilar, A., López Vivanco, G., Camps, C., López-Castro, R., Morán, T., Barneto, I., Rodríguez-Abreu, D., Serna-Blasco, R., Benítez, R., Aguado de la Rosa, C., Palmero, R., Hernando-Trancho, F., Martín-López, J., Cruz-Bermúdez, A., Massuti, B., & Romero, A.
Venue
New England Journal of Medicine
Published
2023-08-10
Volume
389
Issue
6
Pages
504-513
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4382363420
Cited by
484
References
15
FWCI
76.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.